Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: September 11, 2005
Last updated: March 14, 2007
Last verified: March 2007
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Condition Intervention Phase
Gram-Positive Bacterial Infections
Escherichia Coli Infections
Klebsiella Infections
Drug: piperacillin-tazobactam
Phase 4

Study Type: Observational
Study Design: Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.

Resource links provided by NLM:

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Estimated Enrollment: 200
Study Start Date: February 2005

Ages Eligible for Study:   15 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Eligible patients of either sex, 15 years of age or older
  • Patients who are admitted to the department of hematology and oncology
  • Provide written informed consent

Exclusion Criteria:

  • Patients who have hypersensitivity to β-lactam antibiotics
  • Female who are pregnant or breast-feeding
  • Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00167999

Korea, Republic of
Seoul, Korea, Republic of, 133-792
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information Identifier: NCT00167999     History of Changes
Other Study ID Numbers: 0910X-101676
Study First Received: September 11, 2005
Last Updated: March 14, 2007

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Bacterial Infections

Additional relevant MeSH terms:
Communicable Diseases
Bacterial Infections
Gram-Positive Bacterial Infections
Klebsiella Infections
Escherichia coli Infections
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Piperacillin, tazobactam drug combination
Penicillanic Acid
Anti-Bacterial Agents
Anti-Infective Agents
beta-Lactamase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 24, 2017